136 related articles for article (PubMed ID: 33213839)
21. Development of meningococcal polysaccharide conjugate vaccine that can elicit long-lasting and strong cellular immune response with hepatitis B core antigen virus-like particles as a novel carrier protein.
Xu L; Li Z; Su Z; Yang Y; Ma G; Yu R; Zhang S
Vaccine; 2019 Feb; 37(7):956-964. PubMed ID: 30655174
[TBL] [Abstract][Full Text] [Related]
22. The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity.
Schödel F; Moriarty AM; Peterson DL; Zheng JA; Hughes JL; Will H; Leturcq DJ; McGee JS; Milich DR
J Virol; 1992 Jan; 66(1):106-14. PubMed ID: 1370083
[TBL] [Abstract][Full Text] [Related]
23. Modification of Asparagine-Linked Glycan Density for the Design of Hepatitis B Virus Virus-Like Particles with Enhanced Immunogenicity.
Hyakumura M; Walsh R; Thaysen-Andersen M; Kingston NJ; La M; Lu L; Lovrecz G; Packer NH; Locarnini S; Netter HJ
J Virol; 2015 Nov; 89(22):11312-22. PubMed ID: 26339047
[TBL] [Abstract][Full Text] [Related]
24. Site-Specific Modification of Virus-Like Particles for Exogenous Tumor Antigen Display and Minimizing Preexisting Immunity.
Cheng K; Ma N; Liang J; Ma X; Feng Q; Liu G; Xu C; Tang M; Zhang L; Gao X; Xu J; Wang C; Zhu F; Wang X; Li X; Zhao X; Nie G
Small; 2023 Jun; 19(23):e2300125. PubMed ID: 36879481
[TBL] [Abstract][Full Text] [Related]
25. Anti-Aβ antibodies induced by Aβ-HBc virus-like particles prevent Aβ aggregation and protect PC12 cells against toxicity of Aβ1-40.
Feng G; Wang W; Qian Y; Jin H
J Neurosci Methods; 2013 Aug; 218(1):48-54. PubMed ID: 23701997
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis B core-based virus-like particles to present heterologous epitopes.
Roose K; De Baets S; Schepens B; Saelens X
Expert Rev Vaccines; 2013 Feb; 12(2):183-98. PubMed ID: 23414409
[TBL] [Abstract][Full Text] [Related]
27. Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice.
Huang Z; Santi L; LePore K; Kilbourne J; Arntzen CJ; Mason HS
Vaccine; 2006 Mar; 24(14):2506-13. PubMed ID: 16417953
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B virus core particles displaying Mycobacterium tuberculosis antigen ESAT-6 enhance ESAT-6-specific immune responses.
Yin Y; Li H; Wu S; Dong D; Zhang J; Fu L; Xu J; Chen W
Vaccine; 2011 Aug; 29(34):5645-51. PubMed ID: 21689705
[TBL] [Abstract][Full Text] [Related]
29. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype.
Milich DR; Schödel F; Hughes JL; Jones JE; Peterson DL
J Virol; 1997 Mar; 71(3):2192-201. PubMed ID: 9032353
[TBL] [Abstract][Full Text] [Related]
30. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
31. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses.
Jegerlehner A; Tissot A; Lechner F; Sebbel P; Erdmann I; Kündig T; Bächi T; Storni T; Jennings G; Pumpens P; Renner WA; Bachmann MF
Vaccine; 2002 Aug; 20(25-26):3104-12. PubMed ID: 12163261
[TBL] [Abstract][Full Text] [Related]
32. Production and purification of chimeric HBc virus-like particles carrying influenza virus LAH domain as vaccine candidates.
Kazaks A; Lu IN; Farinelle S; Ramirez A; Crescente V; Blaha B; Ogonah O; Mukhopadhyay T; de Obanos MP; Krimer A; Akopjana I; Bogans J; Ose V; Kirsteina A; Kazaka T; Stonehouse NJ; Rowlands DJ; Muller CP; Tars K; Rosenberg WM
BMC Biotechnol; 2017 Nov; 17(1):79. PubMed ID: 29126399
[TBL] [Abstract][Full Text] [Related]
33. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes.
Schödel F; Peterson D; Hughes J; Wirtz R; Milich D
J Biotechnol; 1996 Jan; 44(1-3):91-6. PubMed ID: 8717391
[TBL] [Abstract][Full Text] [Related]
34. Glycoengineered hepatitis B virus-like particles with enhanced immunogenicity.
Joe CCD; Chatterjee S; Lovrecz G; Adams TE; Thaysen-Andersen M; Walsh R; Locarnini SA; Smooker P; Netter HJ
Vaccine; 2020 May; 38(22):3892-3901. PubMed ID: 32284273
[TBL] [Abstract][Full Text] [Related]
35. A VLP library of C-terminally truncated Hepatitis B core proteins: correlation of RNA encapsidation with a Th1/Th2 switch in the immune responses of mice.
Sominskaya I; Skrastina D; Petrovskis I; Dishlers A; Berza I; Mihailova M; Jansons J; Akopjana I; Stahovska I; Dreilina D; Ose V; Pumpens P
PLoS One; 2013; 8(9):e75938. PubMed ID: 24086668
[TBL] [Abstract][Full Text] [Related]
36. Chimeric Hepatitis B core virus-like particles harboring SARS-CoV2 epitope elicit a humoral immune response in mice.
Sazegari S; Akbarzadeh Niaki M; Afsharifar A; Niazi A; Derakhshandeh A; Moradi Vahdat M; Hemmati F; Eskandari MH
Microb Cell Fact; 2023 Feb; 22(1):39. PubMed ID: 36841778
[TBL] [Abstract][Full Text] [Related]
37. Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses.
Zhao M; Bai Y; Liu W; Xiao X; Huang Y; Cen S; Chan PK; Sun X; Sheng W; Zeng Y
BMC Microbiol; 2013 Dec; 13():287. PubMed ID: 24320792
[TBL] [Abstract][Full Text] [Related]
38. DNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV) core protein enhanced Th2 type responses and cleared HBV with an accelerated kinetic.
Yin Y; Wu C; Song J; Wang J; Zhang E; Liu H; Yang D; Chen X; Lu M; Xu Y
PLoS One; 2011; 6(7):e22524. PubMed ID: 21799884
[TBL] [Abstract][Full Text] [Related]
39. [The immunization effects of HBV core antigen and surface antigen fusion protein in mice].
Li L; Tian YJ; Shen H; Zhao XP; Yang DL
Zhonghua Gan Zang Bing Za Zhi; 2009 Apr; 17(4):275-9. PubMed ID: 19403026
[TBL] [Abstract][Full Text] [Related]
40. Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein.
Kingston NJ; Kurtovic L; Walsh R; Joe C; Lovrecz G; Locarnini S; Beeson JG; Netter HJ
Vaccine; 2019 Mar; 37(12):1674-1684. PubMed ID: 30773400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
